LLY

920.66

+0.74%↑

UNH

591.96

+1.78%↑

NVO

117.12

-0.12%↓

JNJ

160.83

+0.76%↑

ABBV

194.81

+0.93%↑

LLY

920.66

+0.74%↑

UNH

591.96

+1.78%↑

NVO

117.12

-0.12%↓

JNJ

160.83

+0.76%↑

ABBV

194.81

+0.93%↑

LLY

920.66

+0.74%↑

UNH

591.96

+1.78%↑

NVO

117.12

-0.12%↓

JNJ

160.83

+0.76%↑

ABBV

194.81

+0.93%↑

LLY

920.66

+0.74%↑

UNH

591.96

+1.78%↑

NVO

117.12

-0.12%↓

JNJ

160.83

+0.76%↑

ABBV

194.81

+0.93%↑

LLY

920.66

+0.74%↑

UNH

591.96

+1.78%↑

NVO

117.12

-0.12%↓

JNJ

160.83

+0.76%↑

ABBV

194.81

+0.93%↑

Home・Stock List・Biogen Inc

Biogen Inc

Closed

Sector Healthcare

185.66 1.82

Buy Sell

Overview

Share price change

24h

Current

Min

180.82

Max

185.74

Key metrics
By Trading Economics
Income	190M 584M
Sales	180M 2.5B
P/E Sector Avg	28.98 113.916
EPS	5.28
Profit margin	23.628
Employees	7,570
EBITDA	237M 919M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+47.31 upside

Market Stats
By TradingEconomics
Market Cap	-345M 28B
Previous open	183.84
Previous close	185.66

News Sentiment

By Acuity

60%

40%

308 / 366 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

N/A / 193.5401 Support & Resistance

Biogen Inc Chart

Past performance is not a reliable indicator of future results.

Related News

6 Sept 2024, 11:00 UTC

Peer Comparison

Price change

Biogen Inc Forecast

Price Target

By TipRanks

47.31% upside

12 Months Forecast

Average 268.55 USD 47.31%

High 320 USD

Low 190 USD

Based on 21 Wall Street analysts offering 12 month price targets forBiogen Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

21 ratings

Buy

Hold

Sell

Based on 21 analysts giving stock ratings to Biogen Inc - Dist in the past 3 months.

Technical Score

By Trading Central

N/A / 193.5401Support & Resistance

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

308 / 366 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Biogen Inc

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company's marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; GAZYVA indicated for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS), and other anti-CD20 therapies. The Company's pipeline includes BIIB074; BAN2401; BIIB061; BIIB067, BIIB124, BIIB074, BIIB118 and TMS-007.